The study of obliterans bronchiolitis immunopathogenisis and therapy after lung transplant.

Research Project

Project/Area Number	25861240
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Respiratory surgery
Research Institution	Chiba University
Principal Investigator	Suzuki Hidemi 千葉大学, 医学(系)研究科(研究院), 助教 (60422226)
Project Period (FY)	2013-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000) Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords	肺移植 / 拒絶反応 / 肺再生 / 自己免疫
Outline of Final Research Achievements	Due to no effective therapies for obliterative bronchiolitis(OB), the leading cause of death in lung transplant patients, there has been an intensive search for pre-clinical models that replicate OB. We initiated the OB model using minor histoincompatible antigen murine orthotopic single-left lung transplants. We reported that minor, but not major, histocompatibility antigens account for the 50% rate of OB after 28 day after transplant in murine orthotopic lung transplants. IL-10 induction was associated with the absence of OB, whereas, OB development was IL-17 dependent.Donor mice derived minor histoincompatible antigen contribute to OB development and IL-17 induction. Strategies to identifyminor histoincompatible antigen and prevent IL-17 induction in clinical lung transplantation could be useful to reduce the risk of OB development.